NASD · Healthcare · Drug Manufacturers - Specialty & Generic · Canada
Canopy Growth Corp is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.
Canopy Growth produces and distributes cannabis products for medical and adult-use purposes in Canada, Europe, and Australia under brands including Spectrum Therapeutics, Tweed, and Wana. The company offers dried flower, pre-rolled joints, edibles, vapes, and capsules through retail systems and direct-to-patient channels. It holds a non-controlling interest in Canopy USA for exposure to the United States market.
From its FY2026 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Canopy Growth Corp stock.
Overvalued: intrinsic value $0.26 per share, market price $0.65, margin of safety -152.7% (as of 2026-10-30).
Its liquidation floor, current assets minus every liability, values the shares at $0.26; the price of $0.65 is 153% above that value.
Leak Score: 37/100 on 9 of 12 signals (On Watch).
All 84 Drug Manufacturers - Specialty & Generic stocks
26 more in this industry show a wider margin of safety.
CGC is overvalued (as of the 2026-10-30 close). Its liquidation floor, current assets minus every liability, values the shares at $0.26; the price of $0.65 is 153% above that value.
$0.26 per share (as of the 2026-10-30 close), against a market price of $0.65. That is a margin of safety of -152.7%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
37 out of 100, which we rate "On Watch", on 9 of 12 value investing signals.